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Abstract
Background: Exon skipping oligonucleotides (ESOs) of 2'O-Methyl (2'OMe) and morpholino chemistry have
been shown to restore dystrophin expression in muscle fibers from the mdx mouse, and are currently being
tested in phase I clinical trials for Duchenne Muscular Dystrophy (DMD). However, ESOs remain limited in their
effectiveness because of an inadequate delivery profile. Synthetic cationic copolymers of poly(ethylene imine) (PEI)
and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various
applications.
Results: We examined whether PEG-PEI copolymers can facilitate ESO-mediated dystrophin expression after
intramuscular injections into tibialis anterior (TA) muscles of mdx mice. We utilized a set of PEG-PEI copolymers
containing 2 kDa PEI and either 550 Da or 5 kDa PEG, both of which bind 2'OMe ESOs with high affinity and form
stable nanoparticulates with a relatively low surface charge. Three weekly intramuscular injections of 5 μg of ESO
complexed with PEI2K-PEG550 copolymers resulted in about 500 dystrophin-positive fibers and about 12% of
normal levels of dystrophin expression at 3 weeks after the initial injection, which is significantly greater than for
injections of ESO alone, which are known to be almost completely ineffective. In an effort to enhance
biocompatibility and cellular uptake, the PEI2K-PEG550 and PEI2K-PEG5K copolymers were functionalized by
covalent conjugation with nanogold (NG) or adsorbtion of colloidal gold (CG), respectively. Surprisingly, using
the same injection and dosing regimen, we found no significant difference in dystrophin expression by Western
blot between the NG-PEI2K-PEG550, CG-PEI2K-PEG5K, and non-functionalized PEI2K-PEG550 copolymers.
Dose-response experiments using the CG-PEI2K-PEG5K copolymer with total ESO ranging from 3–60 μg yielded
a maximum of about 15% dystrophin expression. Further improvements in dystrophin expression up to 20% of
normal levels were found at 6 weeks after 10 twice-weekly injections of the NG-PEI2K-PEG550 copolymer
complexed with 5 μg of ESO per injection. This injection and dosing regimen showed over 1000 dystrophin-
positive fibers. H&E staining of all treated muscle groups revealed no overt signs of cytotoxicity.
Conclusion: We conclude that PEGylated PEI2K copolymers are efficient carriers for local delivery of 2'OMe
ESOs and warrant further development as potential therapeutics for treatment of DMD.
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Background
Steric block oligomers such as of 2'O-methyl (2'OMe) and
phosphorodiamidate morpholino (PMO) oligonucle-
otides possess high affinity for their complementary pre-
mRNA targets and can modulate alternative splicing, cor-
rect aberrant splicing, and induce skipping or inclusion of
specific exons (for reviews see [1,2]). These splice modu-
lating oligonucleotides (SMOs) represent a powerful class
of compounds with broad utility for basic and transla-
tional research and are poised to show rapid growth as
pharmaceuticals. However, for many in vivo applications,
SMOs administered alone show an inadequate delivery
profile for reaching target cell nuclei, necessitating the use
of carriers. Indeed, inefficient delivery of SMOs remains
the foremost limitation to their usefulness as pharmaceu-
ticals.
Duchenne muscular dystrophy (DMD) is a fatal x-linked
disease caused by mutations in the gene encoding the 427
kDa membrane-associated cytoskeletal protein dys-
trophin, resulting in progressive body-wide muscle weak-
ening and death usually in the early to mid third decade
of life. DMD mutations are most often comprised of inser-
tions and deletions that alter the dystrophin reading
frame or encode premature stop codons [3]. These types
of mutations result in production of truncated and non-
functional dystrophin that is rapidly degraded.
Steric block exon skipping oligonucleotides (ESOs) have
been shown in cultured mouse, canine, and human cells
to cause skipping of targeted dystrophin exons, resulting
in production of full-length dystrophin mRNA (minus
only the skipped exons), and restoration of the reading
frame [4-10]. The classical animal model for DMD, the
mdx mouse, has a point mutation in dystrophin exon 23
that produces a premature stop codon. ESOs have been
shown to promote skipping of exon 23 and concomitant
dystrophin expression in skeletal muscles of mdx  mice
after both local and systemic delivery [8,11-17], and this
technology in the context of therapy for DMD has been
recently reviewed [18,19]. However, the efficiency of
2'OMe ESO delivery, and level of concomitant dystrophin
expression in the mdx mouse remains relatively modest
[11,13,16]. Despite the fact that ESOs without a carrier
have progressed to phase I clinical trials, improved carriers
must be developed before the ESO approach can be con-
sidered as a viable therapeutic for improving health and
longevity in DMD patients.
The amine-rich cationic polymer poly(ethylene imine)
(PEI) is a well-studied compound that is effective at con-
densing large plasmid DNA, enabling improved cellular
uptake [20-25]. Although most often applied to plasmid
delivery, recent studies have also documented PEI-
enhanced delivery of small nucleic acid agents such as oli-
gonucleotides and siRNA [26-33]. The positive surface
charge of PEI-nucleic acid polyplexes interacts with nega-
tively charged elements on the cell membrane, stimulat-
ing non-specific receptor-mediated endocytotic uptake
[20,21,24,25,34,35]. Once internalized, the 'proton
sponge effect' enabled by PEI's buffering capacity induces
the rupturing of the endosomal compartment due to
osmotic lysis [34,36-38]. While the intracellular dynamics
of PEI-nucleotide complexes once released from the endo-
some are unknown, oligonucleotides must dissociate
from PEI to reach the nucleus, as the nuclear envelope is
likely impermeable to PEI. Using dual-fluorescence track-
ing we recently showed PEG-PEI copolymers enhanced
SMO delivery to myonuclei of cultured mdx myofibers,
while the copolymers were mainly excluded from entering
the nuclei [39].
The functionality and biocompatibility of PEI is greatly
improved by incorporation of the nonionic linear poly-
mer poly(ethylene glycol) (PEG) into PEG-PEI copoly-
mers [23,24]. The macromolecular properties of PEG-PEI-
oligonucleotide polyplexes are greatly influenced by the
molecular weight of PEI and nature of PEGylation, which
in-turn effects transfection capacity [22,23,40]. We
recently showed that PEG-PEI copolymers made of low
MW PEI2K significantly improved delivery of ESOs to
myofibers of mdx  mice after intramuscular injections
compared to high MW PEI25K copolymers [13]. We
attributed the superior efficacy of the PEI2K-based copol-
ymers to the low surface charge and high stability of the
nanoparticles formed during complexation with ESOs
[41]. Although intramuscular injection of these PEG-PEI-
ESO polyplexes produced significantly more dystrophin-
positive fibers than ESO alone, the level of dystrophin
expression by Western blot reached only 2–5% of the nor-
mal level in TA muscles. Therefore, in this report we eval-
uated whether new injection regimens and further
functionalization of PEG-PEI copolymers with gold nano-
particles might improve dystrophin expression. Our
results show that repeat injections of small amounts of
PEG-PEI-ESO are very effective at transducing dystrophin
expression, reaching up to 20% of normal levels under the
most favorable formulation and injection regimen.
Results
Induction of dystrophin expression following 
intramuscular injection of PEG-PEI-ESOs
The goal of this study was to determine an effective PEG-
PEI-ESO polyplex formulation and injection scheme for
enhanced dystrophin expression after intramuscular
injection into the TA muscle of 6–8 wk old male mdx
mice. The ESO for all experiments was a 2'OMe oligonu-
cleotide that was previously shown to produce specific
skipping of mouse dystrophin exon 23, thereby removing
a point mutation that encodes a premature stop codonBMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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[11,42]. Mice were given three weekly intramuscular
injections of 5 μg of ESO complexed with either
PEI2K(PEG550)10, NG-PEI2K(PEG550)10, or CG-
PEI2K(PEG5K)10 copolymers and were analyzed for dys-
trophin expression at one week after the third injection.
Immunohistochemistry of transverse sections showed
that all three copolymer formulations produced substan-
tially greater expression of dystrophin-positive fibers com-
pared to muscles from un-injected mdx mice (Figure 1).
H&E staining showed morphological integrity to be well
preserved, with no overt signs of muscle necrosis or cyto-
toxic damage (Figure 1). Quantitative evaluation of whole
muscle cross-sections showed that injections with the
PEI2K(PEG550)10-ESO formulation produced 594 ± 120
dystrophin-positive fibers (Figure 2), which corresponds
to roughly 30% of the approximately 2000 fibers in the TA
muscle [11,43].
In accordance with previous studies showing improved
biocompatibility and enhanced cellular uptake of gold-
conjugated nanoparticles [44,45], we hypothesized that
conjugation or adsorption of nanogold (NG) or colloidal
(CG) to PEG-PEI copolymers would improve the potency
of these carriers. Surprisingly, injections with NG-
PEI2K(PEG550)10-ESO and CG-PEI2K(PEG5K)10-ESO
resulted in only 380 ± 36 and 322 ± 24 dystrophin-posi-
tive fibers, respectively, both of which were significantly
less than found with the unconjugated PEI2K(PEG550)10
copolymer (Figure 2A; P < 0.05).
To quantify dystrophin expression, Western blots were
performed on whole muscle transverse sections directly
serial to those on which fiber counts were obtained. Dys-
trophin expression following three weekly injections of
the PEI2K(PEG550)10-ESO polyplex (5 μg ESO per injec-
tion) reached 11.2 +/- 2.4% of the level found in normal
muscles (Figure 2B–C). As expected, dystrophin expres-
sion in control mdx muscles was not detectable, and was
likely less than 1% of normal. The NG-PEI2K(PEG550)10-
ESO and CG-PEI2K(PEG5K)10-ESO formulations resulted
in 7.6 ± 1.0% and 9.8 ± 2.1% of the normal level of dys-
trophin expression, neither of which was statistically dif-
ferent than the unconjugated copolymer (Figure 2B–C).
Although we did not perform injections of ESO without
polymers in this study, we have shown in other studies
that injections of 2'OMe ESO alone, under very similar
dosing and injection regimens as used herein, produced
very low numbers of dystrophin-positive fibers, and
showed no detectable dystrophin on Western blots ([13]
and Sirsi et al., manuscript submitted). Similarly, a previ-
ous study using this ESO delivered without a carrier
showed no improvement in the number of dystrophin
positive fibers over mdx control muscles [43]. The inepti-
tude of 2'OMe ESO delivery without a carrier in the mdx
mouse has led to omitting ESO alone in other studies
examining dystrophin induction following local and sys-
temic delivery [11,16].
Dose-response profile of PEG-PEI-ESO polyplexes
Using the same triple-injection regimen as above, the
dose-response properties of CG-PEI2K(PEG5K)10-ESO
polyplexes was evaluated over a range from 3–60 μg of
total ESO. Dystrophin-positive fibers were detected at all
dosages (Figure 3), but muscles injected with the smallest
test dosage of ESO (1 μg × 3 injections) expressed signifi-
cantly fewer dystrophin-positive fibers than doses of 15,
30, or 60 μg (Figure 4A; P < 0.05). Western analysis
showed that the highest level of dystrophin induction was
achieved using 5 μg of ESO per injection, resulting in 14.2
Dystrophin induction in limb musculature of mdx mice after  intramuscular injections of 2'OMe ESO complexed with cati- onic nanopolymers Figure 1
Dystrophin induction in limb musculature of mdx 
mice after intramuscular injections of 2'OMe ESO 
complexed with cationic nanopolymers. The TA mus-
cles of mdx mice were given 3 weekly intramuscular injec-
tions of various PEG-PEI copolymers complexed with 5 μg of 
ESO and harvested 3 wks after the first injection. Dystrophin 
immunolabeling (Hoechst dye counterstained) at 2 different 
magnifications and H&E staining of serial transverse sections 
from TA muscles from the following groups: (A-A") normal 
age-matched controls, (B-B") mdx untreated, (C-C") mdx 
injected with PEI2K(PEG550)10-ESO, (D-D") mdx injected 
with NG-PEI2K(PEG550)10-ESO, and (E-E") mdx injected 
with CG-PEI2K(PEG5K)10-ESO.BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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Quantitative analysis of dystrophin expression in TA muscles of mdx mice after intramuscular injections of PEG-PEI-ESO poly- plexes Figure 2
Quantitative analysis of dystrophin expression in TA muscles of mdx mice after intramuscular injections of 
PEG-PEI-ESO polyplexes. Muscles were analyzed following 3 weekly intramuscular injections of 5 μg of ESO complexed 
with either PEI2K(PEG550)10, NG-PEI2K(PEG550)10, or CG-PEI2K(PEG5K)10 copolymers, and harvested 3 wks after the first 
injection. (A) Number of dystrophin-positive fibers for each treatment group was obtained from whole transverse sections 
that were immunolabeled for dystrophin. The number of dystrophin-positive fibers was significantly lower in muscles injected 
with NG-PEI2K(PEG550)10-ESO and CG-PEI2K(PEG5K)10-ESO polyplexes compared with the basic PEI2K(PEG550)10-ESO 
formulation (P < 0.05, N = 4 muscles per group). (B) Western blots show dystrophin expression in thick (60 μm) transverse 
cryosections taken directly adjacent to segments used for fiber counts in panel A. Images show blots of dystrophin (top) and 
vinculin (bottom) obtained from the same gel. All samples contained 25 μg of total protein, and dystrophin expression as a per-
cent of normal is indicated in parentheses below each lane. (C) Quantitative western analysis of dystrophin expression as a 
percent of the level in age-matched normal mice for each of the three PEG-PEI-ESO polyplex formulations. No significant dif-
ferences were observed between treatment groups (P > 0.05; N = 4 muscles per group).BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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± 1.6% expression (Figure 4B–C), with apparent satura-
tion at higher doses.
Longer term repeat ESO injections increase dystrophin 
expression
In an attempt to further improve dystrophin expression,
we carried out longer term repeat injection experiments
using the NG-PEI2K(PEG550)10-ESO polyplexes. Mice
were given 10 consecutive intramuscular injections of
NG-PEI2K(PEG550)10-ESO polyplexes (1 or 5 μg of ESO
per injection), with 4 days between injections, and were
harvested at 6 weeks after the first injection. Immunohis-
tochemistry of whole transverse sections showed that this
protocol resulted in marked improvement in ESO delivery
to myofibers, producing extensive regions of intensely
labeled dystrophin-positive fibers (Figure 5). On average,
muscles injected with the 1 and 5 μg of ESO per injection
(10 and 50 μg total ESO over 6 weeks) contained 832 ±
167 and 1225 ± 343 dystrophin-positive fibers, respec-
tively (Figure 6B). The number of dystrophin-positive fib-
Quantitative analysis of dose-response profile of dystrophin  expression after intramuscular injections of CG- PEI2K(PEG5K)10-ESO polyplexes Figure 4
Quantitative analysis of dose-response profile of dys-
trophin expression after intramuscular injections of 
CG-PEI2K(PEG5K)10-ESO polyplexes. Muscles were 
analyzed following 3 weekly intramuscular injections of 1, 5, 
10, or 20 μg of ESO (3, 15, 30, and 60 μg total) complexed 
with CG-PEI2K(PEG5K)10 copolymers, and harvested 3 wks 
after the first injection. (A) Number of dystrophin-positive 
fibers for each dosage was obtained from whole transverse 
sections that were immunolabeled for dystrophin. Number 
of dystrophin-positive fibers was significantly lower for the 1 
μg injections than for all other doses (P < 0.05, N = 4 mus-
cles per group). (B) Quantification of dystrophin expression 
as a percentage of age-matched normal mice for each of the 
4 polyplex dosages based on densitometry of western blots 
(not shown). Samples were prepared from thick (60 μm) 
transverse cryosections taken adjacent to segments used for 
the fiber counts. Each increase in dosage resulted in signifi-
cantly greater level of dystrophin expression, except 
between the 30 μg and 60 μg dosages which reached a pla-
teau.
Dose-response profile of dystrophin expression after intra- muscular injections of CG-PEI2K(PEG5K)10-ESO polyplexes Figure 3
Dose-response profile of dystrophin expression after 
intramuscular injections of CG-PEI2K(PEG5K)10-
ESO polyplexes. The TA muscles of mdx mice were given 3 
weekly intramuscular injections of CG-PEI2K(PEG5K)10 
copolymers complexed with 1, 5, 10, or 20 μg of ESO per 
injection (3, 15, 30, and 60 μg total) and harvested 3 wks 
after the first injection. Images show dystrophin immunolabe-
ling (Hoechst dye counterstained) and H&E staining of serial 
transverse sections from TA muscles for each of the 4 poly-
plex doses.BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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ers after delivery of 10 μg total ESO for 6 weeks was 2.2-
fold greater than found after 15 μg of ESO for 3 weeks
using the same NG-PEI2K(PEG550)10 copolymer. H&E
staining confirmed the increased dystrophin expression
following repeated injections was not associated with any
overt signs of cytotoxicity (Figure 6A).
Western blots further established the potency of the 10-
repeat injection regimen using the NG-PEI2K(PEG550)10-
ESO polyplexes (Figure 6C–D). On average, muscles
injected with 50 μg of ESO expressed 19.1 ± 1.8% of the
normal amount of dystrophin, a level which was previ-
ously shown to be sufficient for improvement in mdx
muscle mechanical properties [43,46,47]. The dystrophin
expression after 50 μg of ESO was significantly greater
than the 8.1 ± 2.8% produced with 10 μg of ESO
(P < 0.05). However, there was exceptionally high varia-
bility in dystrophin expression within the 10 μg group as
the lowest and highest values ranged from 4 to 23%. The
peak level of 23% dystrophin expression after only 10 μg
ESO injected over 6 weeks demonstrates the effectiveness
of the nanopolymer-ESO formulation coupled with a low
dose-high frequency delivery schedule.
Expression of nNOS in mdx muscles treated with PEG-PEI-
ESOs
Muscles from polyplex-treated mdx mice were analyzed
for nNOS expression as evidence for expression of func-
tional dystrophin with an intact N-terminal binding
domain. It was previously shown that nNOS expression is
A 6 week, repeat intramuscular injection, regimen of PEG-PEI-ESO polyplexes produced widespread manifestation of dys- trophin-positive fibers Figure 5
A 6 week, repeat intramuscular injection, regimen of PEG-PEI-ESO polyplexes produced widespread manifes-
tation of dystrophin-positive fibers. Dystrophin immunolabeling of whole transverse sections of TA muscles of mdx mice 
is shown after 10 twice-weekly intramuscular injections of either 1 μg (A-B) or 5 μg (C-D) of ESO complexed with the NG-
PEI2K(PEG550)10 copolymer. Muscles were harvested at 6 wks after the first of the 10 injections. High magnification views of 
four individual regions of each muscle section (boxed) are shown.BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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absent from muscles of mdx mice [48] and may be upreg-
ulated following exon-skipping restoration of dystrophin
expression [11]. Therefore, we asked whether the current
strategy for restoring dystrophin expression increased the
level of nNOS protein localized at the myofiber mem-
brane, where it serves to maintain normal cellular func-
tion in close association with dystrophin. Serial sections
immunolabeled for dystrophin and nNOS showed a very
tight correlation between dystrophin- and nNOS-positive
fibers (Figure 7). Specifically, membrane-associated
nNOS appeared to be expressed only in the mdx muscle
cells that also showed enhanced dystrophin expression,
indicating that ESO-expressed dystrophin was function-
ally intact. As expected, nNOS expression was absent from
mdx un-injected control muscles.
Discussion
The growing opinion that ESOs are on the path to becom-
ing a viable therapeutic option for DMD is well supported
by cell culture and animal data showing specific skipping
Quantitative analysis of dystrophin expression following a 6 week, repeat intramuscular injection regimen of NG- PEI2K(PEG550)10 polyplexes Figure 6
Quantitative analysis of dystrophin expression following a 6 week, repeat intramuscular injection regimen of 
NG-PEI2K(PEG550)10 polyplexes. Tissues were analyzed following 10 twice-weekly intramuscular injections of either 1 or 
5 μg of ESO complexed with NG-PEI2K(PEG550)10 copolymers, and harvested 6 wks after the first injection. (A) Dystrophin 
immunolabeling (Hoechst dye counterstained) and H&E staining of serial transverse sections from TA muscles from the 10 μg 
(1 μg × 10 injections) and 50 μg (5 μg × 10 injections) groups. (B) Number of dystrophin-positive fibers, obtained from whole 
transverse sections immunolabeled for dystrophin, was significantly lower in muscles injected with 10 μg ESO compared with 
the 50 μg group (P < 0.001, N = 4 muscles per group). (C) Western blots showing dystrophin expression in thick (60 μm) 
transverse cryosections taken adjacent to segments used for the fiber counts in panel B. Images show blots of dystrophin (top) 
and vinculin (bottom) obtained from the same gel. All samples contained 25 μg of total protein, and dystrophin expression as a 
percent of normal is indicated in parentheses below each lane. (D) Dystrophin expression determined from Western blots 
reached 20% of normal levels in muscles injected with NG-PEI2K(PEG550)10-ESO containing 50 μg ESO, which was significantly 
greater than the 10 μg group (P < 0.001, N = 4 muscles per group).BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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nNOS expression in mdx mice after treatment with PEG-PEI-ESO Figure 7
nNOS expression in mdx mice after treatment with PEG-PEI-ESO. Membrane-associated nNOS expression is upreg-
ulated in PEG-PEI-ESO treated mdx muscles in regions highly positive for dystrophin expression. TA muscles were given 10 
twice-weekly intramuscular injections of 5 μg of ESO complexed with the NG-PEI2K(PEG550)10 copolymer, and harvested 6 
wks after the first injection. (A-B) Images of serial whole transverse sections immunolabeled for dystrophin (A) and nNOS (B) 
show the correlation in ESO-mediated upregulation of these two membrane-associated proteins. (C) Higher magnification 
images of specific regions from panels A and B show clearly the concomitant (co-localized) upregulation of both dystrophin and 
nNOS in the same set of fibers of the polyplex-injected muscles. As expected nNOS expression in untreated mdx controls was 
negligible.BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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of various targeted exons and resultant induction of nearly
full-length dystrophin [4,6,7,9,11-16,49,50]. However,
there is vigorous debate as to which ESO chemistry may
work best, and what type of carrier compound will pro-
vide adequate delivery to body musculature. ESOs of
phosphorothioate 2'OMe and PMO chemistry have been
the best studied in animal models for DMD and both are
currently being tested in Phase I clinical safety trials [51].
Both 2'OMe and PMO ESOs function by sterically block-
ing pre-mRNA target sequences, and it is thought that they
may be used interchangeably once an optimal sequence
(for a single chemistry) has been empirically determined
[52]. However, fundamental differences in 2'OMe and
PMO backbone chemistry preclude the use of a universal
carrier for efficient delivery. Specifically, PMOs are syn-
thetic compounds that are extraordinarily resistant to
chemical degradation, but they are also charge neutral
which limits cell surface interactions and cellular uptake.
The non-degradable nature of PMOs also raises concerns
over their safety after extended applications In contrast,
2'OMe ESOs are anionic RNA, and despite improved sta-
bility due to their phosphorothioate backbone, remain
somewhat susceptible to degradation, while the negative
charge hinders biodistribution and cellular uptake.
In this study we showed that PEG-PEI copolymers formu-
lated with low MW PEI2K function as effective carriers for
delivery of 2'OMe ESOs to myofibers of mdx mice after
intramuscular injections, resulting in improved levels of
dystrophin expression. Specifically, three weekly intra-
muscular injections of only 5 μg of ESO complexed with
the PEI2K(PEG550)10 copolymer resulted in about 600
dystrophin-positive fibers and about 11% of the normal
level of dystrophin expression at 3 weeks after the initial
injection. Still higher levels of dystrophin expression were
achieved using a twice-weekly injection regimen extended
out to 6 weeks. Specifically, 10 consecutive injections of
the NG-PEI2K(PEG550)10 copolymer complexed with 5
μg of ESO produced over 1200 dystrophin positive fibers
and 20% of normal levels of dystrophin expression. In
regions with the most highly transfected fibers, we
observed a concomitant increase in membrane-associated
nNOS, specifically in dystrophin-positive fibers, in agree-
ment with previous reports using this ESO [11]. Our lab,
as well as other, have demonstrated that intramuscular
injections of 2'OMe ESO alone, using very similar condi-
tions as used herein, produced very few dystrophin-posi-
tive fibers and negligible levels of dystrophin on western
blots [13,43]. In addition, we previously showed that sin-
gle injections of the PEI2K(PEG550)10 copolymer com-
plexed with 20 μg of ESO produced about 460
dystrophin-positive fibers at 3 weeks after the injection,
but western blots showed dystrophin expression was only
2–5% of normal levels [13]. Taken together, the current
results suggest that PEG-PEI copolymers enhance dys-
trophin expression and that repeat injections are more
effective at transfecting a greater number of muscle fibers
than individual injections containing about the same
amount of ESO.
Although the dystrophin expression levels shown in this
report demonstrate the utility of PEG-PEI nanopolymers
for delivery of ESOs, these compounds appear to be some-
what less effective than PMOs. Specifically, Alter et al [14]
recently showed that single intramuscular injections of 10
μg of PMO resulted in up to 60% of the normal level of
dystrophin expression, although this report appeared to
provide only an estimate of efficacy and lacked statistical
validation. Other recent studies of PMOs with conjugated
peptide cell-targeting moieties showed impressive num-
bers of dystrophin-positive fibers, but did not provide a
thorough evaluation of dystrophin expression by western
blots [12].
The PEI2K(PEG550)10 and PEI2K(PEG5K)10 copolymers
utilized in this study were previously shown to form
exceptionally stable complexes when mixed with nega-
tively charged ESO and the surface charge of the resultant
nanoparticulates was relatively low [41]. We propose that
the high stability and low surface charge of these poly-
plexes are two salient features that make them better
suited for in vivo delivery of ESOs than high MW PEI25K-
based copolymers. Specifically, the low polyplex surface
charge favors biodistribution and reduces cytotoxicity,
while the high stability allows the polyplex to remain
associated during extracellular to intracellular trafficking.
Gold nanoparticles such as NG and CG have been shown
to improve biocompatibility and enhance cellular uptake
of various types of cargo in drug delivery applications
[44,45,53,54]. In particular, NG conjugated to low MW
PEI2K showed at least an order of magnitude greater effi-
ciency than PEI25K and was 12 times more potent than
unmodified PEI2K for delivery of plasmid DNA in cell cul-
ture [44]. Unexpectedly, our results showed that neither
covalent conjugation of NG or electrostatic surface coat-
ing with CG of the PEG-PEI copolymers improved ESO
delivery. Polyplex stability assays in PBS showed CG and
NG caused only moderate weakening of polyplex stability
(data not shown), making this an unlikely explanation for
the lack of improved delivery. A possible explanation for
the lack of improvement is that the CG coating was not
stable enough to adhere to the copolymer during delivery.
On the other hand, NG was covalently conjugated to PEG-
PEI, and we postulate that its ineffectiveness was more
likely due to the 1:10 NG to PEI2K ratio, which may have
been too low to improve functionality.
The dystrophin expression achieved in the present study
was accomplished with PEG-PEI carriers that did notBMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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appear to elicit any overt signs of cytotoxicity. This is in
contrast to previous studies using non-PEGylated PEI25K
as a carrier of 2'OMe ESOs, which was ineffective and
resulted in significant damage following only a very lim-
ited number of injections [55,56]. Based on these results,
it was concluded that cationic polymers are unsuitable for
in vivo delivery of AO in skeletal muscle [11,57]. However,
the PEI-nucleotide particles used in these previous studies
undoubtedly had very high positive surface charges,
because they did not contain PEG, which is known to pro-
vide steric shielding of the PEI surface charge. In addition,
dispersion of the highly-charged particles after intramus-
cular injection is probably severely hindered by charge
interactions between the PEI and negatively-charged ele-
ments within the extracellular environment. Therefore, it
is not surprising that these previous muscle transfection
studies with non-PEGylated PEI produced unsatisfactory
results. We suggest that the combination of a low MW PEI
and extensive PEGylation used presently provided a favo-
rable formulation which was both effective and non-toxic.
However, the lack of cytotoxicity observed does not pre-
clude the possibility that some damage to muscle occurs
immediately after injection, resulting in some level of
degeneration-regeneration. This process may underlie to
some extent the high number of dystrophin-positive fib-
ers observed in our 6 week (10 injection) trials. Although
not systematically evaluated, we have observed that short-
term mechanical damage occurs in mdx  muscles after
intramuscular injections of various solutions (even
saline) that does not occur in normal muscle. Because of
the lack of dystrophin, mdx muscles are more susceptible
to mechanical damage than normal muscle. This effect
may be exacerbated to some extent by cationic particles, or
for that matter, any type of carrier compound.
We suggest that the major limitation of the carrier-ESO
formulations described in this report was inadequate car-
rier functionality, and not a lack of intrinsic potency of the
ESO. The ESO used in the present study (designated in the
literature as M23D(+02–18)) has been shown in vitro to
predominantly produce skipping of exon 23, although
some exon 22–23 double skipping does occur [42]. More-
over, in this study we showed that under the most effec-
tive condition, about 50% of fibers were dystrophin-
positive, resulting in about 20% of normal dystrophin
expression. This indicates that on average dystrophin-pos-
itive fibers contained about 40% of the normal level of
dystrophin. A similar calculation based on data reported
by Lu et al [11], and our recent study with TAT-conjugated
copolymers (Sirsi et al., manuscript submitted) suggests
that dystrophin per transfected fiber may reach 75% of
normal levels. Thus, the main limitation with cationic car-
riers seems to be their poor diffusional distribution, as
indicated by large regions in muscles with no apparent
transfection. Thus, further improvements in carrier func-
tionality will likely be required to enable their usage in a
clinical setting for DMD. Our group recently showed that
conjugation of multiple HIV-TAT epitopes to
PEI2K(PEG5K)10 copolymers greatly improved ESO deliv-
ery, using a similar dosing and intramuscular injection
regimen as reported here, resulting in up to 30% dys-
trophin expression (Sirsi et al., manuscript submitted).
Various other types of cell targeting ligands, cell penetrat-
ing peptides, or fusogenic peptides may also be conju-
gated to PEI to improve functionality. Importantly, this
type of peptide-PEI conjugate can likely be formulated for
improved systemic delivery, which will be required to
achieve meaningful therapeutic benefit. PMOs have
already been shown to have limited efficacy after systemic
delivery. For example, intraperitoneal injections into neo-
natal mdx mice of 5 mg/kg/week with PMO-peptide pro-
duced widespread dystrophin in diaphragm muscle, with
low levels of expression observed in limb muscles [12,58].
Conclusion
In this report, we show that PEGylated amine-rich
branched cationic nanopolymers comprised of low MW
PEI2K are effective carriers for delivery of ESOs to myofib-
ers of mdx mice after intramuscular injections. Our results
indicate that high frequency, low-dosage, long-term injec-
tion regimens using these carrier-ESO compounds pro-
vide the most favorable outcome in terms of dystrophin
expression. While other studies have shown improve-
ments utilizing gold nanoparticles, we showed no
enhancement when conjugated to the current PEG-PEI
formulations. Despite the lack of improvement using
these novel conjugations, PEGylated PEI2K copolymers
remain as one of the most efficient carriers for local deliv-
ery of 2'OMe ESOs and warrant further development as
potential therapeutics for treatment of DMD.
Methods
Animals
Male  mdx  mice (C57BL/10ScSn-Dmdmdx/J) and age-
matched 6–9 wk old normal mice (C57BL/10SnJ) were
obtained from Jackson Laboratories (Bar Harbor, ME). All
animals were housed according to NIH and University
guidelines (Drexel University College of Medicine, ULAR
facility, Philadelphia, PA).
Nanopolymer synthesis
The synthesis and physiochemical characterization of the
PEI2K(PEG550)10 and PEI2K(PEG5K)10 copolymers were
previously described [41,59]. Copolymers are designated
using a nomenclature where the subscript indicates the
number of PEG chains grafted per molecule of PEI. For
example, PEI2K(PEG550)10 indicates 10 PEG chains of
550 daltons grafted to each 2 kDa PEI molecule. Nano-
gold (NG) particles were conjugated to PEI primary amine
groups on PEI2K(PEG550)10 coploymers using the Sulfo-BMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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N-  Hydroxy-Succinimido Nanogold labeling reagent
(Nanoprobes, Yaphank, NY). In this reaction, 75 nmols of
PEI2K(PEG550)10 was mixed with 6 nmols of NHS-nano-
gold in 780 μl of sterile water (pH = 8.0). The solution was
incubated for 24 hours on ice, frozen, and subsequently
freeze-dried and stored at -20°C. Adsorption of colloidal
gold (CG) to PEI2K(PEG5K)10 was performed by mixing
300 μl of 5 nM CG particles (Sigma-Aldrich) with 30 mg
of PEI2K(PEG5K)10 (in 1 ml DI H20) and incubating at
4°C overnight. The polymer solution was subsequently
freeze-dried and stored at -20°C. The NG and CG labeled
copolymers are designated as NG-PEI2K(PEG550)10 and
CG-PEI2K(PEG5K)10, respectively.
Preparation of PEG-PEI-ESO polyplexes
The ESO used in all experiments was a 20-mer oligoribo-
nucleotide (5'-GGCCAAACCUCGGCUUACCU-3') previ-
ously shown to cause skipping of dystrophin exon 23 in
mdx  mice [11,16,42]. During synthesis (Trilink, San
Diego, CA) each base was phosphorothioated and con-
tained a methoxy group at the 2' carbon. PEG-PEI-ESO
polyplexes were prepared at a nitrogen to phosphate ratio
of 5 (N:P = 5); where N represents moles of amine on PEI,
and P represents moles of phosphate on ESO. Polyplexes
were formed by the addition of the PEG-PEI copolymer
solution to the ESO solution (in sterile saline). Polyplex
solutions were vortexed briefly, sonicated for 30 min
using a bath sonicator, incubated on ice for 30 min, and
used immediately.
Intramuscular injections of PEG-PEI-ESO polyplexes
Male mdx mice (6–9 weeks of age) were anesthetized with
ketamine/xylazine and shaved for visualization of hind-
limb muscles. A 15 μl volume of PEG-PEI-ESO polyplex
solution at various concentrations was injected bi-later-
ally into the mid-belly portion of TA muscles using a 31
gauge insulin syringe. After recovery from anesthesia,
mice were returned to normal cage activity.
We used both a 3 wk and 6 wk polyplex injection schedule
as follows. For the 3 wk groups, mice were injected on
days 0, 7, and 14; and were harvested on day 21. In one
series of experiments muscles were injected with 5 μg of
ESO (15 μg total) complexed with either the
PEI2K(PEG550)10, NG-PEI2K(PEG550)10, or CG-
PEI2K(PEG5K)10 copolymers. For dose-response analysis
of a single polyplex, muscles were injected with 1, 5, 10,
or 20 μg of ESO (3, 15, 30, and 60 μg total) complexed
with the CG-PEI2K(PEG5K)10 copolymer. For the 6 wk
groups, mice were injected on days 0, 4, 8, 12, 16, 20, 24,
28, 32, and 36; and were harvested on day 42. For this
experiment, muscles were injected with either 1 or 5 μg of
ESO per injection (10 and 50 μg total) complexed with
the NG-PEI2K(PEG550)10 copolymer. For all groups, 2
mice (N = 4 muscles) were analyzed.
Muscle harvest, immunohistochemistry, histology, and 
fiber counts
At designated time points mice were killed and TA mus-
cles were removed, pinned to parafilm-covered cork, snap
frozen in liquid N2-cooled isopentane, and stored at -
80°C. Control muscles were harvested from uninjected
age-matched mdx and normal mice. Transverse frozen sec-
tions (10 μm) were cut from the belly of each TA muscle
using a cryostat (Leica CM 3050 S, Bannockburn, IL) and
melted onto slides for immunohistochemistry and histo-
chemistry. Thick (60 μm) transverse sections, immedi-
ately adjacent to the thin sections were cut in the cryostat
and placed in 1.5 mL centrifuge tubes on dry ice, and
stored at -80°C for subsequent western analysis.
For immunolabeling, muscle sections were blocked with
10% normal goat serum in 1% BSA/PBS for 1 h and then
incubated for 1 h in rabbit polyclonal anti-dystrophin
(1:200; Abcam, Cambridge, MA) or anti-nNOS (1:125;
Invitrogen, Carlsbad, CA). The secondary antibody was
Cy3-Anti-Rabbit IgG (1:500; Jackson Immunoresearch,
West Grove, PA). Slides were coverslipped with Vectash-
ield mounting medium with DAPI (Vector Laboratories,
Burlingame, CA) and imaged (4/10/20× objective; Olym-
pus, AX70, Melville, NY). Composite images of entire
transverse sections were constructed from overlapping
low magnification images using Adobe Photoshop
(Adobe, San Jose, CA). Fiber counts of dystrophin-posi-
tive fibers were obtained using the cell counter function of
ImageJ software (rsb.info.nih.gov/ij/plugins/cell-coun-
ter.html).
Western analysis of dystrophin expression
Sections of frozen TA muscles (60 μm) were extracted in
1.5 ml centrifuge tubes by pipetting up and down in 50 μl
of protein extraction buffer containing 125 mM Tris (pH
6.8), 4% SDS, 2 M Urea, 5% 2-mercaptoethanol, 10%
glycerol, 5 μl of protease inhibitor cocktail (Sigma, St.
Louis, MO) and protease inhibitors calpeptin (100 nM;
Calbiochem, San Diego, CA) and calpain inhibitor I (25
μM; Calbiochem, San Diego, CA). The extract was incu-
bated on ice (15 min), boiled (5 min), and centrifuged
(4000 × g for 5 min), and the supernatant was transferred
to a clean tube. Protein concentration was measured in
extracts using the Coomassie assay (Pierce, Rockford, IL)
and an equal volume of SDS-PAGE sample buffer (125
mM Tris (pH 6.8), 4% SDS, 5% 2-mercaptoethanol, 10%
glycerol and 0.05% bromophenol blue) was added to the
extract. Samples containing 25 μg of total protein were
loaded onto pre-cast SDS-PAGE gels (3% stacking: 7.5%
resolving; Bio-Rad, Hercules, CA) and run at 150 V for 75
min. Gels were transferred to nitrocellulose at 30 V for 16
h and membranes were stained with Ponceau S (Sigma, St.
Louis, MO) to visualize proper transfer and even loading.
Membranes were cut to allow separate immunoblotting ofBMC Biotechnology 2008, 8:35 http://www.biomedcentral.com/1472-6750/8/35
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dystrophin and vinculin and blocked in Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE) for 1 h. Mem-
branes were incubated for 1 h in mouse monoclonal anti-
dystrophin (MANDYS8; Sigma, St. Louis, MO) and anti-
vinculin (VIN1; Sigma, St. Louis, MO) at dilutions of
1:400 and 1:2000, respectively. Donkey anti-mouse
IRDye 800 CW secondary antibody (LI-COR Biosciences,
Lincoln, NE) was applied for 1 h and membranes were
scanned on an Odyssey Infrared Imaging System follow-
ing multiple TBS-T/TBS washes. Odyssey imaging soft-
ware was used for densitometry and the integrated
intensity of sample bands was used for calculating the per-
centage of dystrophin expression as compared to the nor-
mal muscles. For each muscle, 2–3 separate 60 μm
sections were extracted and used in western analysis.
Statistical Analysis
All data are reported as mean values ± SEM. Statistical dif-
ferences between treatment groups were evaluated by
ANOVA (Statview; SAS Institute, Cary, NC).
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